Teva moves closer to Ratiopharm acquisition

"Bloomberg" reports that private equity firm EQT is out of the running, leaving only two bidders.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and Iceland's Actavis are the two finalists in the tender to acquire German generic drug company Ratiopharm GmbH, after Swedish private equity firm EQT Partners AB was eliminated, reports "Bloomberg" according to three sources familiar with the auction.

Media reports had said that Actavis and EQT jointly bid in the Ratiopharm tender. Pfizer Inc. (NYSE: PFE; LSE: PFZ) was also mentioned, but dropped out. The price tag for Ratiopharm is $3.4-4 billion.

Published by Globes [online], Israel business news - - on February 17, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018